aTyr Pharma, Inc. (ATYR) is a Healthcare · Biotechnology company listed on NASDAQ. Price $0.36 (-3.37%), Market cap $0.05B, 52-week low–high $0.40 ~ $6.61.
aTyr Pharma, Inc., a clinical stage biotechnology company, engages in the discovery and development of product candidates that translate tRNA synthetase biology into new therapies for fibrosis and inflammation in the United States. Its lead therapeutic candidate efzofitimod, a selective modulator of NRP2 that is in Phase 3 clinical trial for the treatment of pulmonary sarcoidosis; Phase 2 clinical trial to treat Sarcoidosis and systemic sclerosis- interstitial lung disease (ILDs); and treatment of other ILDs, such as chronic hypersensitivity pneumonitis (CHP) and connective tissue disease related ILD. The company is developing ATYR0101, a fusion protein derived from a domain of aspartyl-tRNA
Financial statements, price targets, institutional (13F) holdings and related news for aTyr Pharma, Inc. are updated in real time on BlackAll Trade.
aTyr Pharma, Inc. trades at $0.36 (-3.37%). Real-time quotes and charts are available on BlackAll Trade.
aTyr Pharma, Inc. has a market cap of about $0.05B.
aTyr Pharma, Inc., a clinical stage biotechnology company, engages in the discovery and development of product candidates that translate tRNA synthetase biology into new therapies for fibrosis and inf